SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) July 17, 1997
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On July 18, 1997, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that
its subsidiary, IDT, Inc., in conjunction with HemoCleanse, Inc.,
has entered into an agreement with The University of Texas M.D.
Anderson Cancer Center to begin pre-clinical studies utilizing
the BioLogic-HT System and disposables in preparation for a Phase
I/II trial to involve thermochemotherapy hemi-perfusion of
patients with pelvic or lower extremity recurrences of different
types of cancer.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: July 17, 1997
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide
Susan Taylor
1.412.429.0673 phone
1.412.279.9455 phone
1.412.279.9690 fax
1.412.279.9447 fax
BIOCONTROL SUBSIDIARY TO ENTER TRIAL WITH M.D. ANDERSON
Pittsburgh, PA - July 17, 1997 - Biocontrol Technology, Inc.
(Nasdaq:BICO) announced today that its subsidiary, IDT, Inc., in
conjunction with HemoCleanse, Inc., has entered into an agreement
with The University of Texas M.D. Anderson Cancer Center to begin
pre-clinical studies utilizing the BioLogic-HT System and
disposables in preparation for a Phase I/II trial to involve
thermochemotherapy hemi-perfusion of patients with pelvic or
lower extremity recurrences of different types of cancer. M.D.
Anderson Cancer Center ranks as one of the nation's most
respected and productive comprehensive cancer centers.
The BioLogic-HT System with its special sorbent suspension
system for delivering extracorporeal whole-body hyperthermia is
the only system that has received Food and Drug Administration
(FDA) approval under two separate Investigational Device
Exemptions (IDEs) for studies on HIV and cancer and offers
several advantages over existing methods of perfusion, minimizing
the physiological and biological changes associated with
extracorporeal heating of the blood.
M.D. Anderson Cancer Center plans to use the BioLogic-HT
System in animal studies to develop the surgical techniques
necessary for a clinical trial on humans and to train and
familiarize its staff in the use of the system. M.D. Anderson is
well known for being a leader in new and innovative treatments
and procedures, and IDT is excited to be involved with such an
impressive institution.
Biocontrol Technology, Inc. has its corporate offices in
Pittsburgh, Pennsylvania and is involved in the development and
manufacture of biomedical devices and environmental products.
IDT, Inc., a wholly-owned subsidiary of Biocontrol also located
in Pittsburgh, PA, holds exclusive worldwide marketing rights to
the BioLogic-HT System and related disposables, while
HemoCleanse, Inc. of West Lafayette, IN, holds the exclusive
worldwide manufacturing rights.
